ライフサイエンスコーパス: pancreatectomy

1 7.3% (distal pancreatectomy) to 22.9% (total pancreatectomy).

2 reasing surgical site infections (SSI) after pancreatectomy.

3 ly associated with poorer survival following pancreatectomy.

4 as associated with higher risk for allograft pancreatectomy.

5 creases of children with KATPHI who required pancreatectomy.

6 y play a role in diabetes secondary to total pancreatectomy.

7 2 patients (68% [95% CI, 49%-88%]) underwent pancreatectomy.

8 bine (825 mg/m2 orally twice daily) prior to pancreatectomy.

9 avin-1 may improve the long-term efficacy of pancreatectomy.

10 fluid administration on morbidity following pancreatectomy.

11 8 (71.2%), hip replacement; and 2276 (1.8%), pancreatectomy.

12 ne cells after beta-cell ablation or partial pancreatectomy.

13 d Whipple procedure and 7 patients had total pancreatectomy.

14 ul islet isolation after near-total or total pancreatectomy.

15 7.5% after hip replacement, and 16.3% after pancreatectomy.

16 elated deaths occurred within 365 days after pancreatectomy.

17 of patients required early readmission after pancreatectomy.

18 a near-total pancreatectomy, and one partial pancreatectomy.

19 pair, colectomy, total hip arthroplasty, and pancreatectomy.

20 ing either pancreaticoduodenectomy or distal pancreatectomy.

21 antly affect QoL in emergency laparotomy and pancreatectomy.

22 hat is unresponsive to diazoxide is subtotal pancreatectomy.

23 mandatory to provide appropriate care after pancreatectomy.

24 .14) for gastrectomy to 1.45 (1.21-1.73) for pancreatectomy.

25 y, and recovery as compared with open distal pancreatectomy.

26 partial pancreatic duct ligation or partial pancreatectomy.

27 y broaden indications for minimally invasive pancreatectomy.

28 odenectomy and 257 +/- 93 minutes for distal pancreatectomy.

29 nding the indications for minimally invasive pancreatectomy.

30 potential cause of recurrence after partial pancreatectomy.

31 ncreatic fistula in patients undergoing left pancreatectomy.

32 is the most frequent complication after left pancreatectomy.

33 in SSI between antibiotic-types after distal pancreatectomy.

34 deemed unsalvageable and required allograft pancreatectomy.

35 opic or surgical means, and partial or total pancreatectomy.

36 ndividuals may be managed medically, without pancreatectomy.

37 ncies and provides real-time feedback during pancreatectomy.

38 y, complications, and overall survival after pancreatectomy.

39 oval has yet to be explored following distal pancreatectomy.

40 colectomy to 71.2% (range, 8.3% to 100%) for pancreatectomy.

41 ized nationwide with no clear guidelines for pancreatectomy.

42 death for lung resection, esophagectomy, and pancreatectomy.

43 ed a pCR following neoadjuvant treatment and pancreatectomy.

44 2 with distal pancreatectomy, 2 with central pancreatectomy, 1 with total pancreatectomy) for failure

45 There were 183 total pancreatectomies, 113 partial pancreatoduodenectomies, 7

46 y (132), distal pancreatectomy (83), central pancreatectomy (13), pancreatic enucleation (10), total

47 an of 4 cycles of preoperative treatment and pancreatectomy, 155 (63%) initiated postoperative chemot

48 after AAA repair (8.8% vs 9.3%; P = .55) and pancreatectomy (17.5% vs 15.9%; P = .40).

49 olectomy: 25.8%; hip replacement: 32.5%; and pancreatectomy: 19.7%) compared with the index hospitali

50 1,191 colectomies, 2,670 cystectomies, 1,514 pancreatectomies, 2,607 proctectomies, 12,228 prostatect

51 with pancreaticoduodenectomy, 2 with distal pancreatectomy, 2 with central pancreatectomy, 1 with to

52 ies, 10 distal pancreatectomies, and 1 total pancreatectomy; 21 total specimens were obtained.

53 5-year survival were good for standard total pancreatectomies (28.6 months and 24.3%, respectively) a

54 creatic gastrinoma resected by means of left pancreatectomy 31 years before, hyperparathyroidism trea

55 omy (13), pancreatic enucleation (10), total pancreatectomy (5), Appleby resection (4), and Frey proc

56 The majority of esophagectomy (77.8%) and pancreatectomy (53.4%) and 48.1% of proctectomy patients

57 IHV)-esophagectomy 1.6%; proctectomy 19.7%; pancreatectomy 6.6%.

58 Of 13,317 pancreatectomies, 6335 (47.6%) were performed by hospita

59 arge portion of the decline in mortality for pancreatectomy (67% of the decline), cystectomy (37%), a

60 erative morbidity was higher following total pancreatectomy (69.0% vs. 38.6% for pancreaticoduodenect

61 gth of stay than patients who underwent open pancreatectomy (7 days vs 9 days; P < 0.001).

62 o 0.95) and 80 patients who underwent distal pancreatectomy (7% vs. 23%; relative risk, 0.32; 95% CI,

63 For distal pancreatectomies (7085 patients; 6.2% mortality), there

64 lyzed; pancreaticoduodenectomy (132), distal pancreatectomy (83), central pancreatectomy (13), pancre

65 redictor of mortality for the performance of pancreatectomy, AAA repair, esophagectomy, or CABG.

66 All patients with PDAC who underwent pancreatectomy after preoperative therapy between 2010 a

67 inical dilemma of balancing the morbidity of pancreatectomy against the risk of malignant transformat

68 d to improve glycemic control after extended pancreatectomy, almost exclusively in patients with chro

69 eneic islet transplantation as well as total pancreatectomy alone (nontransplanted group).

70 level, this projected to 42,320 open distal pancreatectomies and 1908 MIDPs.

71 s reflect the invasiveness of extended total pancreatectomies and the underlying advanced malignant d

72 ancreatitis recipients 1-8 years after total pancreatectomy and autoislet transplantation.

73 mortality rates were significantly lower for pancreatectomy and esophagectomy at Specialized Centers.

74 atify superficial and organ-space SSIs after pancreatectomy and investigate their modifiable risk fac

75 mplications, and long-term outcomes of total pancreatectomy and islet autotransplantation (TP-IAT) in

76 ze factors predicting outcomes after a total pancreatectomy and islet autotransplantation (TP-IAT).

77 Total pancreatectomy and islet autotransplantation is an effec

78 Total pancreatectomy and islet autotransplantation provides su

79 Total pancreatectomy and islet cell autotransplantation (TPIAT

80 Total pancreatectomy and marginal mass islet autotransplantati

81 dings differed between fistulas after distal pancreatectomy and pancreatoduodenectomy.

82 ticoduodenectomy, and 1 patient had a distal pancreatectomy and splenectomy.

83 Overall, 22,366 patients underwent a pancreatectomy and the mortality was 8.1%.

84 luded 9 pancreaticoduodenectomies, 10 distal pancreatectomies, and 1 total pancreatectomy; 21 total s

85 3 partial pancreatoduodenectomies, 79 distal pancreatectomies, and 10 resections for tumor recurrence

86 ions (51 pancreaticoduodenectomies, 18 total pancreatectomies, and 49 distal splenopancreatectomies).

87 Pledge" aims to centralize esophagectomies, pancreatectomies, and proctectomies to hospitals meeting

88 uding 27 with localized tumors (11 underwent pancreatectomy, and 16 had localized nonresectable tumor

89 my, proctectomy, esophagectomy, gastrectomy, pancreatectomy, and hepatectomy for cancer between 2012

90 exenatide, streptozotocin injection, partial pancreatectomy, and high fat diet.

91 DZX), and nine of whom required a near-total pancreatectomy, and one partial pancreatectomy.

92 antation; (4) improving outcomes after total pancreatectomy; and (5) registry considerations for TPIA

93 Pancreaticoduodenectomy and distal pancreatectomy are associated with significant periopera

94 or left pancreatectomy, as indicated); total pancreatectomy as an alternative to high-risk anastomosi

95 n properly weigh the risks and advantages of pancreatectomy as treatment of PDA.

96 e process of the pancreas who underwent open pancreatectomy as well as intraoperative FS analysis bet

97 Central pancreatectomy, as an alternative to standard resection

98 tic fistula (treated with completion or left pancreatectomy, as indicated); total pancreatectomy as a

99 ve analysis of all minimally invasive distal pancreatectomies at University of Pittsburgh Medical Cen

100 All patients undergoing left pancreatectomy at a large tertiary hospital were eligibl

101 to statewide data of patients who underwent pancreatectomy at a tertiary care referral center betwee

102 with PDAC who had undergone post-neoadjuvant pancreatectomy at four hospitals.

103 ronic pancreatitis subjects undergoing total pancreatectomy (autologous islet transplantation).

104 Donor animals underwent partial pancreatectomy, autologous islet preparation, and inject

105 tion (IAT) in patients undergoing completion pancreatectomy because of sepsis or bleeding after pancr

106 identify all adult patients who had elective pancreatectomies between 2007 and 2012.

107 a who received preoperative therapy prior to pancreatectomy between 1990 and 2015.

108 f 290 patients with localized PDAC underwent pancreatectomy between 2010 and 2018 after receiving pre

109 eview of 721 patients who underwent a distal pancreatectomy between February 1986 and February 2009.

110 Six hundred and ninety-three left pancreatectomy cases (439 OLP, 254 LLP) were analyzed.

111 y bypass surgery, oesophagectomy, colectomy, pancreatectomy, cholecystectomy, ventral hernia repair,

112 < .001) and operative characteristics (total pancreatectomy: coefficient, 12 742.31; 95% CI, 10 063.6

113 omes and hospital charge measures for distal pancreatectomy, comparing the surgical approaches and ad

114 uncinate process of the pancreas undergoing pancreatectomy, complete tumor extirpation via either en

115 BD donors (cases) and subjects who underwent pancreatectomy (controls).

116 otransplantation (TPIAT) rather than partial pancreatectomy could represent a major shift in the mana

117 s were collected from the 2016-2018 targeted-pancreatectomy database from the American College of Sur

118 geons' National Surgical Quality Improvement Pancreatectomy Demonstration Project at 37 high-volume c

119 interhospital transfer (IHT) patients after pancreatectomy, describe the characteristics of transfer

120 lications and pancreatic fistulae after left pancreatectomy differ when open versus laparoscopic tech

121 djusted in-hospital mortality for all distal pancreatectomies (DP), pancreatoduodenectomies (Whipple-

122 elopment of PL in patients undergoing distal pancreatectomy (DP) at a single high-volume institution.

123 derwent pancreatoduodenectomy (PD) or distal pancreatectomy (DP) for all indications between 2014 and

124 (ELNs) on staging and survival after distal pancreatectomy (DP) for pancreatic adenocarcinoma (PDAC)

125 ancreatic fistula (CR-POPF) following distal pancreatectomy (DP) is a dominant contributor to procedu

126 te of new-onset diabetes (NODM) after distal pancreatectomy (DP) is not known.

127 l, the early and long-term outcome of distal pancreatectomy (DP) performed by laparoscopy (LapDP) or

128 study was to test the hypothesis that distal pancreatectomy (DP) without intraperitoneal drainage doe

129 ally relevant fistula (CR-POPF) after distal pancreatectomy (DP), and to identify the cut-off of DFA1

130 rgoing pancreatoduodenectomy (PD) and distal pancreatectomy (DP), and to quantify the delivery of opt

131 ring on pancreatic fistula rate after distal pancreatectomy (DP).

132 y (PD, n = 218), central (n = 16), or distal pancreatectomy (DP, n = 96).

133 erformed in pancreatic specimens after total pancreatectomy due to complications and after placing ex

134 Among all 623 patients who underwent pancreatectomy during the study period, 134 (21.5%) were

135 baboons (Papio hamadryas) underwent partial pancreatectomy, followed by continuous infusion of EXE o

136 data on esophagectomies, gastrectomies, and pancreatectomies for cancer from the NHS Hospital Episod

137 s of a retrospective cohort including distal pancreatectomies for PDAC from 34 centers in 11 countrie

138 Among 1212 distal pancreatectomies for PDAC, 345 patients underwent MIDP,

139 A total of 434 consecutive total pancreatectomies for primary pancreatic or periampullary

140 rgoing laparoscopic spleen-preserving distal pancreatectomy for benign or low-grade malignant tumors

141 erwent laparoscopic spleen-preserving distal pancreatectomy for benign or lowgrade malignant tumors i

142 s during pancreaticoduodenectomy; and distal pancreatectomy for benign/borderline neoplasm of pancrea

143 All patients undergoing pancreatectomy for cancer between 2012 and 2018 were inc

144 st, islet autografts, infused at the time of pancreatectomy for chronic pancreatitis, are not subject

145 absolute reduction in 30-day mortality after pancreatectomy for each 20% increase in the degree of ce

146 chemotherapy after preoperative therapy and pancreatectomy for pancreatic ductal adenocarcinoma (PDA

147 Patients undergoing pancreatectomy for pancreatic ductal adenocarcinoma betw

148 patients who underwent potentially curative pancreatectomy for pancreatic ductal adenocarcinoma were

149 ients who underwent preoperative therapy and pancreatectomy for pancreatic ductal adenocarcinoma.

150 ents (n = 18, >= 19 years old) who underwent pancreatectomy for pancreatobiliary cancer.

151 Patients undergoing pancreatectomy for PDAC at 2 institutions from 2000 to 2

152 chemotherapy and/or (chemo)radiation before pancreatectomy for PDAC between January 2010 and Decembe

153 s new information on how prognosis following pancreatectomy for PDAC evolves over time, adjusting for

154 of TPIAT as valuable alternative to partial pancreatectomy for PDAC patients with a high risk of pos

155 chemotherapy after preoperative therapy and pancreatectomy for PDAC was of clinical benefit.

156 Patients requiring pancreatectomy for PDAC were prospectively included.

157 Total pancreatectomy for presumed painful chronic pancreatitis

158 a in patients undergoing near-total or total pancreatectomy for severe chronic pancreatitis.

159 2 with central pancreatectomy, 1 with total pancreatectomy) for failure to progress (14) and bleedin

160 Patients who underwent pancreatectomies from 2005 to 2014 were identified from

161 n margins) collected prospectively during 32 pancreatectomies from February 27, 2013, to January 16,

162 s, among patients undergoing elective distal pancreatectomy from 1998 to 2009 in the Nationwide Inpat

163 ents with PDAC who underwent robotic or open pancreatectomy from 2011 to 2016 with 24-month follow-up

164 Tissue was isolated during pancreatectomy from eight patients with CHI and from adu

165 e: lung resection, esophagectomy, colectomy, pancreatectomy, gastrectomy, abdominal aortic aneurysm r

166 he Whipple procedure group than in the total pancreatectomy group (median survival 19 months vs 4 mon

167 s 12.4%, P < 0.0001) was improved in robotic pancreatectomy group with no differences in perioperativ

168 sophagectomy: >=41/yr, gastrectomy: >=16/yr, pancreatectomy: >=26/yr, and hepatectomy: >=76/yr).

169 Four of six patients with total pancreatectomy had islet yields exceeding 5000 islet equ

170 r outcomes of MIDP compared with open distal pancreatectomy have been reported.

171 Complications after pancreatectomy have been shown to prohibit the administr

172 nificant difference in the incidence of post-pancreatectomy hemorrhage, delayed gastric emptying, inf

173 A policy that limits access to low-volume pancreatectomy hospitals will increase round-trip drivin

174 They also can be cured by selective partial pancreatectomy; however, unlike those with a K(ATP) foca

175 Standard total pancreatectomy, if needed, is associated with good long-

176 reatectomy was not inferior compared to open pancreatectomy in a high-volume experienced center for o

177 9], P < 0.001) and especially transfer after pancreatectomy in low volume centers (OR = 3.76, CI95%[2

178 ts who experienced major complications after pancreatectomy in low volume hospitals had greater odds

179 nced hands, the rates of complications after pancreatectomy in patients 80 years or older compared to

180 formed as an alternative approach for distal pancreatectomy in selected patients.

181 unders using instrumental variable analysis, pancreatectomy is associated with a statistically signif

182 Central pancreatectomy is associated with an excellent pancreati

183 mplemented, early drain removal after distal pancreatectomy is associated with better outcomes.

184 Readmission after pancreatectomy is common, but few data compare patterns

185 Distal pancreatectomy is the standard procedure for removal of

186 Laparoscopic distal pancreatectomy (LDP) reduces postoperative morbidity, ho

187 The clinical pathway for laparoscopic distal pancreatectomy (LDP) versus open (ODP) for nonmalignant

188 Laparoscopic left pancreatectomy (LLP) is associated with favorable outcom

189 ntly associated with survival at the time of pancreatectomy lost power over time.

190 rgery during 2001 to 2014 for esophagectomy, pancreatectomy, lung resection, or cystectomy.

191 Total pancreatectomy may be required in locally advanced or ce

192 ection factors for minimally invasive distal pancreatectomy (MIDP) and identify actual risk factors f

193 of open (ODP) and minimally invasive distal pancreatectomy (MIDP) are equivalent for benign lesions.

194 conversion during minimally invasive distal pancreatectomy (MIDP) for pancreatic ductal adenocarcino

195 Interest in minimally invasive distal pancreatectomy (MIDP) has grown in recent years, but cur

196 cal outcomes after minimally invasive distal pancreatectomy (MIDP) with open distal pancreatectomy (O

197 raining program in minimally invasive distal pancreatectomy (MIDP), according to the IDEAL framework

198 ses Morbidity" to 0% for "Procedure-Targeted Pancreatectomy Mortality." For Essentials models, averag

199 ectomy (n = 968), proctectomy (n = 1250), or pancreatectomy (n = 1068) were categorized based on freq

200 nts undergoing hepatectomy (n = 2811) and/or pancreatectomy (n = 1092) from January 1997 to December

201 t was relevant in certain subgroups (upfront pancreatectomy (n = 117; P = 0.049); without VR or NAT (

202 ncreatoduodenectomy (n = 514; 88.2%), distal pancreatectomy (n = 62; 10.6%), or total pancreatectomy

203 tal pancreatectomy (n = 62; 10.6%), or total pancreatectomy (n = 7; 1.2%).

204 ), Whipple or Beger procedure (n=14), distal pancreatectomy (n=8), or lateral pancreaticojejunostomy

205 75%)], tail resections [n = 16 (15%)], total pancreatectomies [n = 5 (5%)], and segment resections [n

206 he SMA-margin in specific subgroups (upfront pancreatectomy, N0 patients without NAT, N+ patients wit

207 juvant chemotherapy between robotic and open pancreatectomy, nor was approach an independent predicto

208 istal pancreatectomy (MIDP) with open distal pancreatectomy (ODP) in patients with pancreatic ductal

209 e treatment burden compared with open distal pancreatectomy (ODP), but studies on institutional train

210 r adverse outcomes compared with open distal pancreatectomy (ODP).

211 opensity-matched comparison with open distal pancreatectomy (ODP).

212 ery after minimally invasive and open distal pancreatectomy (ODP).

213 h favorable outcomes compared with open left pancreatectomy (OLP).

214 let yield compared with those who had distal pancreatectomy or lateral pancreaticojejunostomy.

215 rgical beta-cell replication models (partial pancreatectomy or partial duct ligation), representing t

216 rgest for patients who were readmitted after pancreatectomy (OR 0.56, 95% CI 0.45-0.69) and aortobife

217 eplacement (OR, 0.97; 95% CI, 0.91-1.03), or pancreatectomy (OR, 1.02; 95% CI, 0.76-1.36).

218 isease (OR, 2.28; 95% CI, 1.23-4.24), distal pancreatectomy (OR, 1.77; 95% CI, 1.11-2.84), and postop

219 , gastrectomy, hysterectomy, lung resection, pancreatectomy, or prostatectomy were identified retrosp

220 mplexities of chronic pancreatitis and total pancreatectomy outcomes and postsurgical diabetes outcom

221 k of death after hepatectomy (P < 0.001) and pancreatectomy (P < 0.001).

222 tive abdominal aortic aneurysm repair (AAA), pancreatectomy (PAN), and esophagectomy (ESO) as primary

223 f 596,222 patients undergoing esophagectomy, pancreatectomy, partial or total gastrectomy, colectomy,

224 Characteristics of pancreatectomy patients (March 2016-August 2017) were re

225 Robotic pancreatectomy patients had a shorter length of stay tha

226 Total pancreatectomy patients had larger median tumor size (4

227 Total pancreatectomy patients had more lymph nodes harvested (

228 For pancreatectomy patients, mortality increases with increa

229 from 1 to 14 gastrectomies, and from 2 to 31 pancreatectomies per surgeon per year.

230 cilities performing </=25, 26 to 65, and >65 pancreatectomies per year was 456, 20, and 9, respective

231 ty), there were 2 cut-offs (13 and 25 distal pancreatectomies per year), but neither was an independe

232 Pancreatectomies performed at 2 institutions from 2007 t

233 The proportion of distal pancreatectomies performed via minimally invasive approa

234 ated from pancreatic specimen during partial pancreatectomy performed for PDAC.

235 undergoing pancreaticoduodenectomy or distal pancreatectomy [POPF: pasireotide (n = 152), 9% vs place

236 e low-dose streptozotocin (MLDS) and partial pancreatectomy (Ppx).

237 2013 to 2017, pre, intra, and perioperative pancreatectomy processes have evolved, and multiple post

238 my, aortic valve replacement, esophagectomy, pancreatectomy, pulmonary resection, hepatectomy, colect

239 Of these, 50 underwent allograft pancreatectomy (Px) and 196 did not (no-Px).

240 y induced in male Sprague Dawley rats by 90% pancreatectomy (Px).

241 We hypothesized that robot-assisted distal pancreatectomy (RADP) was superior to LDP as a result of

242 safety of the preoperative regimen, and the pancreatectomy rate.

243 Pancreatectomy rates were examined within Health Service

244 ice (PANC PPARgamma(-/-)), normoglycemic 60% pancreatectomy rats (Px), normoglycemic and hyperglycemi

245 inforcement of stapled closure during distal pancreatectomy reduces the rate of fistula formation.

246 Morbidity after pancreatectomy remains unacceptably high.

247 Analysis of readmissions after pancreatectomy reveals it to be a poor quality of care m

248 There is agreement that pancreatectomies should be centralized.

249 , definitive surgical management with distal pancreatectomy should be undertaken in patients with rea

250 Only pancreatectomy showed a notable decrease in strength of

251 We obtained pancreatectomy specimens from 20 patients with chronic p

252 precursor lesions, PanINs, from prophylactic pancreatectomy specimens of patients from four different

253 Measure the caseload of pancreatectomies that influences their short-term outcom

254 For pancreatectomy, the adjusted odds of individual mortalit

255 AT during nonemergency preemptive completion pancreatectomy through the pancreaticoduodenectomy.

256 ctal procedures, esophagectomy, gastrectomy, pancreatectomy, thyroidectomy, coronary artery bypass gr

257 This study simulates the regionalization of pancreatectomies to assess its impact on spatial access

258 unresponsive to medical therapy will require pancreatectomy to control the hypoglycemia.

259 ining program to teach robot-assisted distal pancreatectomy to surgeons at an academic institution an

260 ted with mortality ranging from 7.3% (distal pancreatectomy) to 22.9% (total pancreatectomy).

261 Total pancreatectomy (TP) removes the source of the pain, wher

262 tapled left pancreatectomy with stapled left pancreatectomy using mesh reinforcement of the staple li

263 e resection margins (22.2% vs. 43.7%) (total pancreatectomy vs. pancreaticoduodenectomy, respectively

264 perineural invasion (90.7% vs. 91.8%) (total pancreatectomy vs. pancreaticoduodenectomy, respectively

265 Hepatectomy or completion pancreatectomy was accomplished in 2 patients that remai

266 tes of resection in their geographic region, pancreatectomy was associated with a statistically signi

267 The annual-caseload of pancreatectomy was calculated for each hospital facility

268 Robotic pancreatectomy was not inferior compared to open pancrea

269 Pancreatectomy was performed in 4322 of 8323 patients ev

270 Minimally invasive distal pancreatectomy was performed increasingly in later study

271 ospital quality, postoperative mortality for pancreatectomy was two times higher in the least central

272 phagectomies, 12,622 gastrectomies, and 9116 pancreatectomies were examined.

273 etherlands (2005 to 2013) only 10% of distal pancreatectomies were in a minimally invasive fashion an

274 A total of 8957 distal pancreatectomies were included in this analysis, of whic

275 gectomies, 20,362 lung resections, and 2,844 pancreatectomies were included.

276 Eleven of these pancreatectomies were performed at the time of repeat tr

277 Extended total pancreatectomies were performed in 54% of cases, with ar

278 Central pancreatectomies were performed mainly for neuroendocrin

279 Transfers after pancreatectomy were associated with high rates of FTR, e

280 patients who developed diabetes after total pancreatectomy were candidates for the autologous transp

281 /partial gastrectomy, major hepatectomy, and pancreatectomy were identified using the National Inpati

282 Overall, 19,938 patients who underwent pancreatectomy were included, 1164 (5.8%) of whom were t

283 patients and 20 control patients undergoing pancreatectomy were studied.

284 but, with the exception of surgical partial pancreatectomy, were not extensively beta-cells.

285 oach has been the move to minimally invasive pancreatectomy, which continues to gain broader acceptan

286 incidence and indications for late allograft pancreatectomy while on continued immunosuppression for

287 safety and outcomes of the largest cohort of pancreatectomy with arterial resection (P-AR).

288 sive pancreatic adenocarcinoma who underwent pancreatectomy with curative intent.

289 Total pancreatectomy with intraportal islet autotransplantatio

290 Total pancreatectomy with islet autotransplantation (TP-IAT) i

291 on research gaps and opportunities in total pancreatectomy with islet autotransplantation (TPIAT) fo

292 ain but has not been widely applied to total pancreatectomy with islet autotransplantation (TPIAT).

293 Total pancreatectomy with islet autotransplantation is perform

294 ereditary and idiopathic CP undergoing total pancreatectomy with islet autotransplantation.

295 100 consecutive patients undergoing central pancreatectomy with pancreaticogastrostomy from January

296 The patient underwent total pancreatectomy with splenectomy.

297 ized controlled trial comparing stapled left pancreatectomy with stapled left pancreatectomy using me

298 ancer recurrence-free survival after radical pancreatectomy, with a Harrell's concordance index of 0.

299 onal case of esophagectomy, gastrectomy, and pancreatectomy would reduce 30-day mortality odds by 3.4

300 ated by eliminating hospitals performing <20 pancreatectomies/yr, and reassigning patients to the nex